大疱性类天疱疮患者继发感染危险因素的研究进展

doi:10.35541/cjd.20220694

Abstract

Abstract: 【Abstract】 Secondary infection is the leading cause of death in patients with bullous pemphigoid. Early identification of risk factors for secondary infection in patients with bullous pemphigoid can improve their prognosis. This review summarizes the relationships of secondary infection in bullous pemphigoid with clinical characteristics, laboratory indicators, drug treatment, and duration of hospitalization, providing a reference for clinical evaluation and treatment.

Key words: Pemphigoid, bullous, Infection, Risk factors, Therapy, Length of stay, Clinical features

Ren Weiqi, Zou Yaru, Pan Min. Risk factors for secondary infection in patients with bullous pemphigoid[J]. Chinese Journal of Dermatology,2023,e20220694. doi:10.35541/cjd.20220694

References ［37］

［1］	Persson M, Harman KE, Vinogradova Y, et al. Incidence, prevalence and mortality of bullous pemphigoid in England 1998-2017: a population⁃based cohort study［J］. Br J Dermatol, 2021,184（1）:68⁃77. doi: 10.1111/bjd.19022.
［2］	Cyr P, Lim D, Caruana M, et al. Bullous pemphigoid⁃associated mortality rate in a Canadian tertiary referral centre［J］. J Cutan Med Surg, 2022,26（4）:386⁃392. doi: 10.1177/1203475422108 8562.
［3］	Chen X, Zhang Y, Luo Z, et al. Prognostic factors for mortality in bullous pemphigoid: a systematic review and meta⁃analysis［J］. PLoS One, 2022,17（4）:e0264705. doi: 10.1371/journal.pone.026 4705.
［4］	Kridin K, Shihade W, Bergman R. Mortality in patients with bullous pemphigoid: a retrospective cohort study, systematic review and meta⁃analysis［J］. Acta Derm Venereol, 2019,99（1）:72⁃77. doi: 10.2340/00015555⁃2930.
［5］	Kridin K, Schwartz N, Cohen AD, et al. Mortality in bullous pemphigoid: a systematic review and meta⁃analysis of standardized mortality ratios［J］. J Dermatol, 2018,45（9）:1094⁃1100. doi: 10.1111/1346⁃8138.14503.
［6］	Bastuji⁃Garin S, Joly P, Lemordant P, et al. Risk factors for bullous pemphigoid in the elderly: a prospective case⁃control study［J］. J Invest Dermatol, 2011,131（3）:637⁃643. doi: 10. 1038/jid.2010.301.
［7］	Roujeau JC, Lok C, Bastuji⁃Garin S, et al. High risk of death in elderly patients with extensive bullous pemphigoid［J］. Arch Dermatol, 1998,134（4）:465⁃469. doi: 10.1001/archderm.134.4. 465.
［8］	毕兆华, 冯博惠, 李久宏, 等. 大疱性类天疱疮患者发生感染的分析［J］. 中国皮肤性病学杂志, 2019,33（4）:400⁃404. doi: 10.13735/j.cjdv.1001⁃7089.201810017.
［9］	Holtsche MM, Goletz S, van Beek N, et al. Prospective study in bullous pemphigoid: association of high serum anti⁃BP180 IgG levels with increased mortality and reduced Karnofsky score［J］. Br J Dermatol, 2018,179（4）:918⁃924. doi: 10.1111/bjd.16553.
［10］	Joly P, Benichou J, Lok C, et al. Prediction of survival for patients with bullous pemphigoid: a prospective study［J］. Arch Dermatol, 2005,141（6）:691⁃698. doi: 10.1001/archderm.141.6.691.
［11］	Phoon YW, Fook⁃Chong SM, Koh HY, et al. Infectious complications in bullous pemphigoid: an analysis of risk factors［J］. J Am Acad Dermatol, 2015,72（5）:834⁃839. doi: 10.1016/j.jaad.2015.01.029.
［12］	中华医学会皮肤性病学分会, 中国医师协会皮肤科医师分会. 自身免疫性表皮下大疱病诊疗共识（2022）［J］. 中华皮肤科杂志, 2022,55（1）:1⁃11. doi: 10.35541/cjd.20210532.
［13］	楼小航, 刘继峰, 吴纪龙, 等. 大疱性类天疱疮患者感染分析［J］. 中华医院感染学杂志, 2017,27（9）:2009⁃2011,2019. doi: 10.11816/cn.ni.2017⁃163672.
［14］	Kridin K，Bergman R. Assessment of the prevalence of mucosal involvement in bullous pemphigoid［J］. JAMA Dermatol, 2019, 155（2）:166⁃171. doi:10.1001/jamadermatol.2018.5049.
［15］	Chen J, Mao X, Zhao W, et al. Assessment of the characteristics and associated factors of infectious complications in bullous pemphigoid［J］. Front Immunol, 2020,11:1607. doi: 10.3389/fimmu.2020.01607.
［16］	Miyagawa F, Nakajima A, Ogawa K, et al. Composite EBV⁃negative marginal zone lymphoma and angioimmunoblastic T⁃cell lymphoma presenting as multiple subcutaneous nodules［J］. Eur J Dermatol, 2020,30（4）:427⁃429. doi: 10.1684/ejd.2020.3810.
［17］	Li F, Bian W, Wu Y, et al. Bacterial skin infections in hospitalized patients with bullous pemphigoid［J］. Adv Skin Wound Care, 2021,34（7）:365⁃370. doi: 10.1097/01.ASW.0000 752704.10152.30.
［18］	姚香君, 张琪, 王婷, 等. 656例自身免疫性大疱病住院患者皮肤感染的危险因素及病原学分析［J］. 中国麻风皮肤病杂志, 2021,37（8）:494⁃498. doi: 10.12144/zgmfskin202108494.
［19］	Ren Z, Narla S, Hsu DY, et al. Association of serious infections with pemphigus and pemphigoid: analysis of the Nationwide Inpatient Sample［J］. J Eur Acad Dermatol Venereol, 2018,32（10）:1768⁃1776. doi: 10.1111/jdv.14961.
［20］	Oka M, Fukumoto T. Bullous pemphigoid in which eruption developed exclusively on preexisting eruption of vitiligo vulgaris［J］. Case Rep Dermatol, 2020,12（1）:33⁃36. doi: 10.1159/000 505829.
［21］	Soine EJ, Nelson PS, Nesbitt LT Jr. A patient with coexistent bullous pemphigoid and primary membranous glomerulonephropathy［J］. J Am Acad Dermatol, 2009,60（6）:1042⁃1044. doi: 10.1016/j.jaad.2008.08.032.
［22］	Chen YJ, Juan CK, Chang YT, et al. Association between inflammatory bowel disease and bullous pemphigoid: a population⁃ based case⁃control study［J］. Sci Rep, 2020,10（1）:12727. doi: 10.1038/s41598⁃020⁃69475⁃0.
［23］	Narita YM, Horie C, Hirahara K, et al. Bullous pemphigoid complicated by cytomegalovirus disease as a manifestation of immune reconstitution inflammatory syndrome: retrospective analyses of our institutional cases and literature review［J］. Int J Dermatol, 2018,57（2）:202⁃208. doi: 10.1111/ijd.13799.
［24］	Kamiya K, Aoyama Y, Suzuki T, et al. Possible enhancement of BP180 autoantibody production by herpes zoster［J］. J Dermatol, 2016,43（2）:197⁃199. doi: 10.1111/1346⁃8138.13042.
［25］	Monshi B, Gulz L, Piringer B, et al. Anti⁃BP180 autoantibody levels at diagnosis correlate with 1⁃year mortality rates in patients with bullous pemphigoid［J］. J Eur Acad Dermatol Venereol, 2020,34（7）:1583⁃1589. doi: 10.1111/jdv.16363.
［26］	Delli FS, Sotiriou E, Lazaridou E, et al. Total IgE, eosinophils, and interleukins 16, 17A, and 23 correlations in severe bullous pemphigoid and treatment implications［J］. Dermatol Ther, 2020,33（6）:e13958. doi: 10.1111/dth.13958.
［27］	Kamata A, Kurihara Y, Funakoshi T, et al. Basement membrane zone IgE deposition is associated with bullous pemphigoid disease severity and treatment results［J］. Br J Dermatol, 2020,182（5）:1221⁃1227. doi: 10.1111/bjd.18364.
［28］	盖晓磊, 李思哲, 左亚刚. 大疱性类天疱疮患者血清及疱液嗜酸性粒细胞阳离子蛋白水平检测［J］. 中华皮肤科杂志, 2020,53（12）:1008⁃1011. doi: 10.35541/cjd.20191115.
［29］	Lehman JS, Khunger M, Lohse CM. Infection in autoimmune bullous diseases: a retrospective comparative study［J］. J Dermatol, 2013,40（8）:613⁃619. doi: 10.1111/1346⁃8138.12175.
［30］	Sugiura K, Sugiura N, Yagi T, et al. Cryptococcal cellulitis in a patient with bullous pemphigoid［J］. Acta Derm Venereol, 2013,93（2）:187⁃188. doi: 10.2340/00015555⁃1385.
［31］	Casals DS, Nunes Ede A, Maruta CW, et al. Disseminated cytomegalovirus disease as a cause of prolonged fever in a bullous pemphigoid patient under systemic steroid therapy［J］. J Dermatol, 2003,30（4）:332⁃336. doi: 10.1111/j.1346⁃8138.2003.tb00396.x.
［32］	Tremblay C, Friedmann D. Kaposi sarcoma associated with iatrogenic immunosuppression: a rare complication of bullous pemphigoid treatment［J］. J Cutan Med Surg, 2017,21（5）:449⁃451. doi: 10.1177/1203475417712247.
［33］	Boughrara Z, Ingen⁃Housz⁃Oro S, Legrand P, et al. Cutaneous infections in bullous pemphigoid patients treated with topical corticosteroids［J］. Ann Dermatol Venereol, 2010,137（5）:345⁃351. doi: 10.1016/j.annder.2010.03.015.
［34］	刘景业, 尹莉, 尹志强, 等. 45例大疱性类天疱疮初次住院患者临床回顾性分析［J］. 实用皮肤病学杂志, 2015,（4）:253⁃256. doi: 10.11786/sypfbxzz.1674⁃1293.20150404.
［35］	Messingham KN, Cahill MP, Kilgore SH, et al. TSST⁃1+Staphylococcus aureus in bullous pemphigoid［J］. J Invest Dermatol, 2022,142（4）:1032⁃1039.e6. doi: 10.1016/j.jid.2021.08.438.
［36］	Abdat R, Waldman RA, de Bedout V, et al. Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series［J］. J Am Acad Dermatol, 2020,83（1）:46⁃52. doi: 10.1016/j.jaad.2020.01.089.
［37］	Cao P, Xu W, Zhang L. Rituximab, omalizumab, and dupilumab treatment outcomes in bullous pemphigoid: a systematic review［J］. Front Immunol, 2022,13:928621. doi: 10.3389/fimmu.2022. 928621.

[1]	Mycobacteriosis Research Group, China “Belt and Road” Dermatology Alliance, Division of Dermatology and STI Diagnosis, Chinese Association on Leprosy. Expert consensus on the clinical diagnosis and treatment of cutaneous tuberculosis in China （2024） [J]. Chinese Journal of Dermatology, 2024, 57(5): 426-434.
[2]	Liu Yi, Qu Ying, Lei Wenzhi, Liu Xiaogang, Pan Weihua, Zhang Chao. Clinical efficacy of salt-packing therapy in the treatment of pyogenic granuloma [J]. Chinese Journal of Dermatology, 2024, 0(4): 20230553-e20230553.
[3]	Zhang Dimin, Cao Cheng, Zhou Miaoni, Sheng Anqi, Lin Fuquan, Xu Ai′e. Analysis of disease control rate and its influencing factors in patients with progressive non-segmental vitiligo after combined treatment with compound betamethasone injection [J]. Chinese Journal of Dermatology, 2024, 57(4): 350-354.
[4]	Yan Rufan, Liao Jieyue, Guo Ziyu, Yao Nan, Zhou Wenyu, Luo Shuaihantian, Zhang Guiying, Zhao Ming. Pathogenesis and targeted therapy of pemphigus [J]. Chinese Journal of Dermatology, 2024, 57(4): 374-378.
[5]	Ge Xinhong, Ma Yingdong, Jiao Yaning, Liu Lingling, Zhou Mei, Zi Wei, Li Bowen. Analysis of efficacy and safety of 532-nm picosecond laser in the treatment of early-stage facial seborrheic keratosis [J]. Chinese Journal of Dermatology, 2024, 57(4): 359-362.
[6]	Yue Shuzhen, Shu Ye, Luo Yangyang, Li Keyao, Zhang Yuanyuan, Tang Jianping, Wei Zhu. Efficacy and safety of omalizumab in the treatment of chronic urticaria in children: a retrospective study [J]. Chinese Journal of Dermatology, 2024, 57(4): 354-358.
[7]	Yan Kexin, Xu Xiulian. Nanomedicine: a new strategy for the diagnosis and treatment of melanoma [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230109-e20230109.
[8]	Zong Yangyongyi, Ma Chujun, Su Zhonglan. Eczematization following the treatment of psoriasis with biological agents: pathogenesis and management [J]. Chinese Journal of Dermatology, 2024, 0(3): 20220578-e20220578.
[9]	Hospital for Skin Diseases, Chinese Academy of Medical Sciences, National Center for STD Control, Chinese Center for Disease Control and Prevention, Venereology Group, Chinese Society of Dermatology, Chinese Association Rehabilitation of Dermatology . Chinese expert consensus on the diagnosis and treatment of Mycoplasma genitalium infection （2024） [J]. Chinese Journal of Dermatology, 2024, 57(3): 201-208.
[10]	Wang Qianqiu, Zheng Xiaoli, Du Fangzhi, Zhang Xu. Stop syphilis transmission: new situation and new strategies [J]. Chinese Journal of Dermatology, 2024, 57(3): 209-212.
[11]	Chinese Society of Dermatology, National Center for STD Control, Chinese Center for Disease Control and Prevention, China Dermatologist Association, Chinese Association Rehabilitation of Dermatology. Guideline for the diagnosis and treatment of Chlamydia trachomatis urogenital infection in China （2024） [J]. Chinese Journal of Dermatology, 2024, 57(3): 193-200.
[12]	Liu Jia, Gu Yinghua, He Xiaoning, . Treatment and disease burden of hereditary angioedema [J]. Chinese Journal of Dermatology, 2024, 0(3): 20220205-e20220205.
[13]	Dai Yeqin, Song Xiuzu. Application of hair follicle transplantation and follicular cell suspension transplantation in the treatment of vitiligo [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230274-e0230274.
[14]	China Dermatologist Association, Chinese Society of Dermatology, Dermatology Branch of China International Exchange and Promotive Association for Medical and Health Care, State Key Laboratory of Complex Severe and Rare Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases. Expert consensus on the application and management of therapeutic drugs for atopic dermatitis （2024） [J]. Chinese Journal of Dermatology, 2024, 57(2): 97-108.
[15]	Na Jun, Li Ruoyu, Zhong Shaomin, Yang Li, Wu Yan. Diagnosis and treatment of rosacea in the real world: a survey on the current status [J]. Chinese Journal of Dermatology, 2024, 57(2): 127-133.

Risk factors for secondary infection in patients with bullous pemphigoid

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［37］

Related Articles 15

Metrics

Comments

Recommended 10